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Available online 9 February 2016Epithelial regeneration is a key process for the recovery from ulcerative colitis (UC). Here we demonstrate that a
disintegrin andmetalloproteinase-17 (ADAM17), amain sheddase for tumor necrosis factor (TNF)-α, is essential
for defensive epithelial properties against UC by promoting epithelial cell growth and goblet cell differentiation
inmouse and human. Mice with systemic deletion of Adam17 developed severe dextran sulfate sodium-induced
colitis when compared to mice with myeloid cell Adam17 deletion or control littermates. ADAM17 was predom-
inantly expressed by regenerating epithelia in control mice, and its loss or inhibition attenuated epidermal
growth factor receptor (EGFR) activation, epithelial proliferation, mucus production and barrier functions.
Conversely, ectopic EGFR stimulation promoted epithelial regeneration thereby partially rescuing the severe
colitis caused by ADAM17 deﬁciency. In UC patients, epithelial ADAM17 expression positively correlated with
both cell proliferation and goblet cell number. These ﬁndings suggest that maintaining ADAM17–EGFR epithelial
signaling is necessary for the recovery from UC and would be beneﬁcial to therapeutic strategies targeting
ADAM17-mediated TNF-α shedding.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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ADAMs (a disintegrin and metalloproteinases) are multifunctional
proteins involved in ectodomain shedding of transmembrane proteins
and thereby regulate cell adhesion, migration, and cell–cell communica-
tion. Ectodomain shedding, which is characterized by proteolytic releasetegrin and metalloproteinase;
factor receptor; MMP, matrix
CE, tumor necrosis factor-α
DSS, dextran sulfate sodium;
ic–polycytidylic acid; BrdU,
tigen; pEGFR, phosphorylated
activated protein kinase; PI3K,
nd activator of transcription 3;
gy, Keio University School of
2, Japan.
kada@z6.keio.jp,
. This is an open access article underof extracellular domains of membrane-bound proteins, is a crucial post-
translational regulator for the function and availability of membrane-
bound proteins. The human genome contains 25 ADAMs including four
pseudogenes, and of the 21 ADAM proteins there are 13 proteolytic and
8 nonproteolytic ADAMs (Mochizuki and Okada, 2007, Blobel, 2005,
Edwards et al., 2008). Proteolytic ADAMs share the metalloproteinase
domain of matrix metalloproteinases (MMPs), and a typical proteo-
lytic ADAM protein is comprised of propeptide, metalloproteinase,
disintegrin-like, cysteine-rich, epidermal growth factor (EGF)-like,
transmembrane, and cytoplasmic domains (Mochizuki and Okada,
2007, Blobel, 2005, Edwards et al., 2008). Previous studies have
shown that several proteolytic ADAMspecies contribute to inﬂammatory
diseases and cancers by shedding pro-inﬂammatory cytokines, growth
factors and their receptors in addition to the degradation of extracellular
proteins including extracellular matrix (ECM) components (Shimoda
et al., 2007, 2014, Murphy, 2008).
ADAM17, also called tumor necrosis factor (TNF)-α converting
enzyme (TACE), was originally identiﬁed as a proteinase responsible
for the ectodomain shedding of the membrane-bound form of TNF-α
(Black et al., 1997). Subsequent studies showed that ADAM17 is also
involved in the processing of various membrane-bound moleculesthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
115M. Shimoda et al. / EBioMedicine 5 (2016) 114–124including EGF receptor (EGFR) ligands, CD44, Kit ligand and L-selectin
(Blobel, 2005). This ectodomain shedding event regulates key functions
of these molecules that impact immune responses and cancer devel-
opment in vivo (Scheller et al., 2011). However, the early lethality of
Adam17-deﬁcient mice has hampered the analysis of ADAM17 func-
tions in postnatal development, adult homeostasis and disease
(Peschon et al., 1998). To circumvent this issue, we generated condi-
tional Adam17-deﬁcient mice, which exhibit no phenotype in adult
animals, enabling us to analyze the roles of ADAM17 in various disease
models (Horiuchi et al., 2007, La Marca et al., 2011).
Ulcerative colitis (UC) is an intractable inﬂammatory bowel disease
(IBD), showing diffuse mucosal inﬂammation that extends proximally
from the rectum. Onset of UC typically occurs in the second and third
decades of life and the majority of affected individuals deteriorate to
chronic disease (Farmer et al., 1993, Ordas et al., 2012). Many factors
affecting innate and adaptive immunity and epithelial barrier, which
include genetic predisposition, eating habits and changes in intestinal
ﬂora, may contribute to the complexity of UC, but the underlying
mechanisms are still poorly understood (Ananthakrishnan, 2015).
Metalloproteinases including ADAMs are produced by many different
cell types and regulate intestinal immune responses as well as wound
healing (Khokha et al., 2013, Shimoda and Khokha, 2013). Actually,
mucosal ADAM17 activity is reported to increase in UC patients
(Brynskov et al., 2002). Transient upregulation of ADAM17 activity is
implicated in promotion of neutrophil transepithelial migration and
high colitis activity (Cesaro et al., 2009) and ADAM17-dependent
shedding of TNF-α from intestinal epithelial cells initiates a pro-
inﬂammatory state and mucosal atrophy in a mouse model of total
parenteral nutrition (Feng et al., 2015), whereas mice with reduced
ADAM17 levels were shown to exhibit increased sensitivity to colitis
(Chalaris et al., 2010, Brandl et al., 2010). Therefore, the functions of
ADAM17 and the origin of ADAM17-producing cells in UC remain
unclear. Previous studies have shown that anti-TNF-α therapy is
useful for human inﬂammatory diseases with excess TNF-α production
(Abraham and Cho, 2009), but at present, most of emerging selective
ADAM17 inhibitors show various side-effects and are limited to phase
I and II trials (Duffy et al., 2011). It is still an open question whether
ADAM17 is a promising target for UC treatments.
In this study, we examined the role of ADAM17 in colitis by
developing dextran sulfate sodium (DSS)-induced colitis using two
different conditional Adam17-deﬁcientmice, i.e.micewith systemic dele-
tion by the inducibleMx1-Cre gene of Adam17 (Adam17ﬂox/ﬂoxMx1-Cre+)
or those with its deletion in myeloid cells by the lysozyme M promoter
(Adam17ﬂox/ﬂoxLysM-Cre+). We also studied the signiﬁcance of the
ADAM17-EGFR pathway in cell proliferation and goblet cell maintenance
by utilizing colonic epithelial cell lines, and ﬁnally investigated the
relevance of our ﬁndings to human UC tissues. Our data demonstrate a
protective function of epithelial ADAM17 as a gatekeeper molecule
against intestinal inﬂammation.
2. Materials and Methods
2.1. Study Approval
All animal experiments were conducted following ARRIVE standard
in accordance with protocols approved by the Institutional Animal Care
and Use Committee of the Keio University School of Medicine (Protocol
No. 071120, No. 10236-2). For experiments using human samples,
informed consent for the study was obtained from the patients in
accordance with the Declaration of Helsinki and IRB approval of the
Keio University School of Medicine (Protocol No. 2012-377-2).
2.2. Generation of Conditional ADAM17-Deﬁcient Mice
The following mouse strains were used: Adam17ﬂox/ﬂox, Mx1-Cre
and LysM-Cre mice (Horiuchi et al., 2007). Adamﬂox/ﬂox mice andAdamﬂox/ﬂoxMx1-Cre knock-in mice were generated as previously
described (Horiuchi et al., 2007, Kuhn et al., 1995). To allow temporal
systemic deletion of ADAM17, six-week-old Adam17ﬂox/ﬂoxMx1-Cre
mice were injected i.p. with 250 μg of pIpC (polyinosinic–polycytidylic
acid) (Sigma-Aldrich) three times at 2-day intervals (Horiuchi et al.,
2007). Recombination of the Adam17 gene in Adam17ﬂox/ﬂoxMx1-Cre
mice was conﬁrmed by PCR of genomic DNAs isolated from colon and
liver tissues (Horiuchi et al., 2007). As for a control, Adam17ﬂox/ﬂox
mice were treated with pIpC three times. Adamﬂox/ﬂoxLysM-Cre mice,
which delete the ADAM17 gene in myeloid cells, were also generated
as described previously (Horiuchi et al., 2007, Clausen et al., 1999). All
the mice were maintained under a 12 hour light–dark cycle with ad
libitum access to regular food and water in a speciﬁc-pathogen free
environment. In all experiments with Adam17ﬂox/ﬂoxCremice, age- and
sex-matched littermates were served as controls.2.3. DSS-Induced-Colitis
Age- and sex-matched male mice (8-week-old) were adminis-
tered with 3% DSS (molecular weight: 36,000–50,000 Da; MP Bio-
medicals) in their drinking water for 8 days and thereafter they
were provided with regular water for 4 days (Wirtz et al., 2007).
They were observed and weighed every day for determination of
percent weight, which was calculated as follows: (weight at day
X / weight at day 0) × 100. For histological and gene expression
analyses, the mice were sacriﬁced at days 0, 4, 8 or 12 after the
initiation of DSS treatment. For recovery experiments, recombinant
transforming growth factor (TGF)-α (8 μg per injection) or PBS was
intraperitoneally injected into the mice at days 0, 2, 4 and 6 after
DSS administration.
Protocols for all other procedures are provided in the Supplementary
Materials and Methods.3. Results
3.1. Systemic Deletion of ADAM17 Develops Severe Inﬂammation in
Response to DSS
To investigate the effects of ADAM17 on the pathogenesis of colitis,
we used pIpC-treated Adam17ﬂox/ﬂoxMx1-Cre+ mice, which show
systemic deletion of Adam17 (Horiuchi et al., 2007). Themice exhibited
a normal phenotype without any evident histological defects in the
colon mucosa or spontaneous colitis up to 6 weeks after pIpC injection
(data not shown). DSS-induced colitis,which is a rapid and reproducible
model of colitis and mimics human UC, was developed by the adminis-
tration of 3% DSS in drinking water for 8 days to age- and sex-matched
Adam17ﬂox/ﬂoxMx1-Cre+ mice and their control littermates, followed by
4 days of regular drinkingwater. Both Adam17ﬂox/ﬂoxMx1-Cre+mice and
control mice developed signs of colitis 4 days after DSS administration.
However, colitis was signiﬁcantly worse in Adam17ﬂox/ﬂoxMx1-Cre+
mice, as evidenced by severe weight loss (p b 0.05 and p b 0.01 at days
7, 8, 9 and 10) and a high mortality rate (p b 0.05 at day 12) compared
to controls (Fig. 1a). Adam17ﬂox/ﬂoxMx1-Cre+ mice showed signiﬁcantly
shorter colons than controls after treatment (p b 0.05 and p b 0.01 at
days 4 and 8) (Fig. 1b). Microscopically, ulcer lesions appeared to
increase in Adam17ﬂox/ﬂoxMx1-Cre+ mice compared to control
mice (Fig. 1c). According to the methods by Egger et al. (1997),
we determined the histological scores (Supplementary Fig. 1),
and found that mean areas of Grade III lesion and Crypt damage
scores at days 8 and 12 are signiﬁcantly increased in Adam17ﬂox/
ﬂoxMx1-Cre+ mice compared to control littermates (Grade III
lesion, p b 0.05 and p b 0.01; Crypt damage score, p b 0.01) (Fig. 1d
and e). These data indicate a protective role of ADAM17 against
DSS-induced colitis.
Fig. 1. Systemic deletion ofAdam17 but not its deletion inmyeloid cells develops severe inﬂammation in response to DSS. a. Percentweight change (left panel) and survival (right panel) of
8-week-old control (Control) (n = 10 mice) and Adam17ﬂox/ﬂoxMx1-Cre+ (ΔAdam17_Mx1) mice (n = 10 mice) after DSS administration. Bars, mean ± s.d.; *, p b 0.05; **, p b 0.01. b.
Macroscopic images of representative colons from control and ΔAdam17_Mx1 mice at day 8 after DSS challenge (left panel). Scale bar, 1 cm. Right panel shows the ratio of length/
initial weight of the colon from these mice at days 0, 4, 8 and 12. Bars, mean ± s.d.; n = 3–5 colon tissues; **, p b 0.01. c. Representative HE-stained colon sections from control (left
panels) and ΔAdam17_Mx1 mice (right panels). Upper panels, whole colon sections from ascending colon (A) to rectum (R); lower panels, representative high-power view. Ulcer
lesions are indicated by red lines. Scale bars, 50 μm. d. Grade III lesions in control and ΔAdam17_Mx1mice at days 0, 4, 8 and 12 after DSS administration. Bars, mean ± s.d.; n = 3–6
colon tissues; *, p b 0.05; **, p b 0.01. e. Crypt damage score in control and ΔAdam17_Mx1 mice at days 0, 4, 8 and 12 after DSS administration. Bars, mean ± s.d.; n = 3–6 colon
tissues; **, p b 0.01. f. Percent weight change (left panel) and survival (right panel) of 8-week-old control (Control) (n = 8 mice) and Adam17ﬂox/ﬂoxLysM-Cre+ (ΔAdam17_LysM) mice
(n = 9 mice) after DSS administration. Bars, mean ± s.d. g. Macroscopic images of representative colon tissues from control and ΔAdam17_LysMmice at day 8 of DSS challenge (left
panel). Scale bar, 1 cm. Right panel shows the ratio of length/initial weight of the colon from these mice at days 0, 4, 8 and 12. Bars, mean ± s.d.; n = 3–5 colon tissues. h. Crypt
damage score in control and ΔAdam17_LysMmice at days 0, 4, 8 and 12 after DSS administration. Bars, mean ± s.d.; n = 3–5 colon tissues. i. Inﬁltrating leukocytes in colon sections
from control and Adam17ﬂox/ﬂoxMx1-Cre+ (ΔAdam_Mx1) mice after DSS administration. Quantiﬁcation of immunostained cells per high-power ﬁeld is shown. Bars, mean ± s.d.; n =
3–6 colon tissues. Results between the two independent groups were determined by Student's t-test. For survival analysis, Kaplan–Meier test was used. P values smaller than 0.05 are
indicated on respective plots.
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117M. Shimoda et al. / EBioMedicine 5 (2016) 114–1243.2. Loss of Myeloid Cell-Derived ADAM17 Has No Effect on Development
of Colitis
ADAM17 is known as the major TNF-α sheddase in myeloid cells
(Horiuchi et al., 2007). We therefore examined the possible involve-
ment of myeloid cell-derived ADAM17 in DSS-induced colitis by using
Adam17ﬂox/ﬂoxLysM-Cre+ mice, which lack ADAM17 in the myeloid
compartment (Horiuchi et al., 2007). These mice showed no evident
histological abnormalities in the colon (data not shown). Unexpectedly,
DSS-induced colitis in Adam17ﬂox/ﬂoxLysM-Cre+ mice was less severe
compared to the colitis in Adam17ﬂox/ﬂoxMx1-Cre+ mice, showing
similar severity to control mice, based on the observations of weight
loss and survival (Fig. 1f). Length of the colon and histology of the colitis
at different time points were comparable between Adam17ﬂox/ﬂoxLysM-
Cre+ mice and control littermates (Fig. 1g and h). Immunohistochemi-
cal analyses of individual inﬁltrated leukocytes demonstrated no
signiﬁcant differences in the number of neutrophils, macrophages
or T-lymphocytes at various time points post-DSS administration
between Adam17ﬂox/ﬂoxMx1-Cre+ and the control (Fig. 1i and Supple-
mentary Fig. 2). These data indicate that myeloid cell-derived ADAM17
has no impact on DSS-induced colitis model.Fig. 2. Adam17ﬂox/ﬂoxMx1-Cre+mice exhibit decreases in epithelial cell proliferation, number of
(distal, proximal and cecum) and liver evaluated by RT-PCR. b. Immunoblot of ADAM17 in the d
after DSS challenge. β-Actin was used as a loading control. c. Representative ADAM17-immun
challenge. The highlighted areas are magniﬁed to the right. Scale bars, 100 μm. d. Quantiﬁcatio
epithelial cells is shown. Bars, mean ± s.d.; n = 3–4 colon tissues; *, p b 0.05. e. Images and
Alcian-Blue-stained sections from control and ΔAdam17_Mx1mice at days 0 and 8 after DSS
Alcian-Blue-positive goblet cells per 100 epithelial cells is shown in the right panel. Bars, m
measuring the translocation of FITC-dextran, given by gavage, into mouse serum after 4 h. Bar
were determined by Student's t-test. P values smaller than 0.05 are indicated on respective plo3.3. ADAM17 is Expressed in Regenerating Epithelial Cells and Involved in
Epithelial Barrier Functions
The pIpC-induced recombination in Adam17ﬂox/ﬂoxMx1-Cre mice is
known to occur in various organs with different efﬁciency, leading to
almost complete recombination in the bone marrow, liver and spleen
(Horiuchi et al., 2007). As shown in Fig. 2a, Adam17ﬂox/ﬂoxMx1-Cre+
mice showed effective gene recombination in the distal colon after
pIpC injection at a similar level to the liver, as indicated by detection
of increased null gene and decreased ﬂoxed ADAM17. Protein
expression of ADAM17 was negligible in colon tissues from untreated
Adam17ﬂox/ﬂoxMx1-Cre+ and control mice, but at day 8 after DSS admin-
istration, ADAM17was expressed in controlmice, butwas still absent in
Adam17ﬂox/ﬂoxMx1-Cre+ colon tissue (Fig. 2b). Immunohistochemical
analysis demonstrated that ADAM17 is expressed predominantly by
epithelial cells of the DSS-induced inﬂamed colon in control mice,
although negligible expression of ADAM17 was detected in the crypts
of Adam17ﬂox/ﬂoxMx1-Cre+ mice (Fig. 2c). Further analysis indicated
that bromodeoxyuridine (BrdU)-positive or proliferation cell nuclear
antigen (PCNA)-positive intestinal epithelial cells are decreased in
Adam17ﬂox/ﬂoxMx1-Cre+ mice compared to the control at day 8 aftergoblet cells and barrier function. a. Efﬁciency of Cre-induced Adam17 excision in the colon
istal colon from control and Adam17ﬂox/ﬂoxMx1-Cre+ (ΔAdam17_Mx1) mice at days 0 and 8
ostained colon sections from control and ΔAdam17_Mx1 mice at days 0 and 8 after DSS
n of number of BrdU-positive epithelial cells per gland and percentage of PCNA-positive
quantiﬁcation of colonic goblet cells in control and ΔAdam17_Mx1mice. Representative
challenge are indicated in the left panel. Scale bars, 100 μm. Quantiﬁcation of number of
ean ± s.d.; n = 4 colon tissues; **, p b 0.01. f. In vivo permeability assay performed by
s, mean ± s.d.; n = 4–6 mice; **, p b 0.01. Results between the two independent groups
ts.
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In addition, the number of Alcian-Blue-positive goblet cells was
signiﬁcantly decreased in Adam17ﬂox/ﬂoxMx1-Cre+ mice at day 8 com-
pared to control mice (Fig. 2e, p b 0.01). Importantly, gastrointestinal
permeability, as determined by serum FITC-dextran intensity 4 h after
gavage, was signiﬁcantly increased in Adam17ﬂox/ﬂoxMx1-Cre+ mice at
day 8 compared to controlmice (Fig. 2f, p b 0.01). Therefore, both regen-
eration and barrier integrity are reduced in the absence of epithelial
ADAM17.
3.4. Loss of ADAM17 Greatly Inhibits EGFR Activation and Mucus Produc-
tion in Colonic Epithelia
Considering the decreased proliferation observed in the colon
tissues of DSS-treated Adam17ﬂox/ﬂoxMx1-Cre+ mice, we examined the
downstream impact on EGFR signaling by measuring the expression
of total and phosphorylated EGFR (pEGFR) in colon tissues from
Adam17ﬂox/ﬂoxMx1-Cre+ mice and their control littermates at day 0
(untreated) and day 8 after treatment with DSS. As shown in Fig. 3a,
increased expression of pEGFR was detected in the distal colon tissues
of littermate controls at day 8 after DSS challenge, but only weak or
negligible expression was seen in Adam17ﬂox/ﬂoxMx1-Cre+ mice.
Immunohistochemical expression of pEGFR was clearly observed inFig. 3. Loss of ADAM17 abrogates EGFR signaling in colonic epithelia. a. Immunoblot of EGFR and
at days 0 and 8 after DSS administration. β-Actin was used as a loading control. b. Phosphorylat
control and ΔAdam17_Mx1mice at day 8 after DSS administration. NI, non-immune IgG (Contr
colonic crypts from control and ΔAdam17_Mx1mice at days 0 and 8 after DSS administration.
pEGFR and EGFR in isolated colonic crypts from control and ΔAdam17_Mx1mice at day 8 after
MUC2 by RT-qPCR in isolated colonic crypts from control and ΔAdam17_Mx1mice at day 8 aft
p b 0.01. f. Dot immunoblot of MUC2 in isolated colonic crypts from control and ΔAdam17_M
and GAPDHwas used as a loading control. Results between the two independent groups were dthe colonic epithelia of control mice at day 8, but negligible staining was
present in those of Adam17ﬂox/ﬂoxMx1-Cre+mice (Fig. 3b). Colonic epithe-
lia of both Adam17ﬂox/ﬂoxMx1-Cre+ and control mice expressed EGFR and
TGF-α, a major EGFR ligand (Fig. 3b). To further study the morphological
changes and pEGFR expression in colonic epithelia, we isolated colonic
crypts from the distal colon. The morphology of isolated colonic crypts
was almost identical in control and Adam17ﬂox/ﬂoxMx1-Cre+ mice under
untreated conditions, but the crypts from DSS-treated mice at day 8
showed different morphology: large regenerative crypts were present
among small fragmented crypts in the control, whereas most crypts
from Adam17ﬂox/ﬂoxMx1-Cre+ mice were fragmented (Fig. 3c). Similar to
the in vivo setting, the crypts isolated from Adam17ﬂox/ﬂoxMx1-Cre+ mice
showed lower levels of ADAM17 and pEGFR expression compared
to control mice (Fig. 3d). In addition, by real-time quantitative PCR
(RT-qPCR) (Fig. 3e) and dot blotting using anti-MUC2 antibody
(Fig. 3f), the crypts from DSS-treated Adam17ﬂox/ﬂoxMx1-Cre+ mice
showed less expression of MUC2, a mucin polypeptide speciﬁc for
goblet cells, compared to control crypts. Since the secretion of
mucins into the intestinal lumen by goblet cells creates the ﬁrst line
of defense against microbial encroachment (Peterson and Artis, 2014),
ADAM17 appears to protect defective epithelial barriers of the colon
against inﬂammation and damage through goblet cell differentiation
or maintenance.pEGFR in the distal colon from control and Adam17ﬂox/ﬂoxMx1-Cre+ (ΔAdam17_Mx1)mice
ed EGFR (pEGFR), EGFR and TGF-α immunostaining of representative colon sections from
ol for anti-pEGFR and anti-EGFR antibodies). Scale bars, 100 μm. c. Morphology of isolated
Arrows indicate regenerative large crypts. Scale bars, 50 μm. d. Immunoblot of ADAM17,
DSS administration. β-Actin was used as a loading control. e. Relative gene expression of
er DSS administration. Bars, mean ± s.d.; n = 4 independently isolated colonic crypts; **,
x1mice at day 8 after DSS administration. Two μg of tissue lysates were loaded per dot
etermined by Student's t-test. P values smaller than 0.05 are indicated on respective plots.
119M. Shimoda et al. / EBioMedicine 5 (2016) 114–1243.5. ADAM17–EGFR Signaling is Responsible for Cell Proliferation and
Goblet Cell Differentiation
To address the link between the ADAM17–EGFR signaling and the
epithelial cell proliferation and goblet cell differentiation, we utilized
two human colonic epithelial cell lines, Caco-2 and LS174T cells, both
of which express ADAM17, EGFR and its ligand TGF-α (Supplementary
Fig. 4). As shown in Fig. 4a, pEGFR expression was suppressed by
treatment with ADAM17-selective inhibitor S-44029 (Supplementary
Fig. 5) or an EGFR inhibitor AG1478 in both Caco-2 and LS174T cells.
S-44029 inhibits LPS-induced TNF-α release in THP-1 cells with an
IC50 of 5.9 μM (a gift from Kaken Pharmaceutical Co., LTD.; Patent No.
WO2003/022801), and has 10-fold more selectivity for the ADAM17
over ADAM10 and N37-fold selectivity over MMP-1, -2, -3, -8, -9, -13,Fig. 4. ADAM17–EGFR signaling is responsible for cell proliferation and goblet cell phenotype. a
on pEGFR and EGFR expression in Caco-2 and LS174T cells. β-Actin was used as a loading cont
Caco-2 and LS174T cell growth. Bars, mean± s.d.; n= 3wells; **, p b 0.01. c. Effect of S-44029 o
stained LS174T cells in the presence of S-44029 or AG1478 inhibitor are indicated in the left pan
(right panel). Bars, mean± s.d.; n= 4 dishes; *, p b 0.05; **, p b 0.01. d. Effect of S-44029 or AG1
examined by RT-qPCR. Bars, mean ± s.d.; n = 4 dishes; *, p b 0.05; **, p b 0.01. e. Time-lapse ce
LY294002) or STAT3-speciﬁc inhibitor (100 μM, S3I) on Caco-2 and LS174T cell growth. Bars, m
U0126. f. Effect of MEK-speciﬁc (U0126), PI3K-speciﬁc (LY294002) or STAT3-speciﬁc inhibitor
immunoblot (upper panel) and RT-qPCR (lower panel). Bars, mean± s.d.; n = 3 dishes; **, p b
immunoblot analysis. Results between the two independent groups were determined by Stud
ANOVA followed by Bonferroni's post-hoc testing. P values smaller than 0.05 are indicated on r-14 or -17 in in vitro enzyme assays (Kawasaki et al., 2006). Importantly,
these inhibitors signiﬁcantly reduced cell growth as well (Fig. 4b,
p b 0.01). LS174T cells are endowed with characteristics of goblet cells
such as mucus granules (Van Klinken et al., 1996), and here we found
that the size and number of mucus granules, stained by Alcian-Blue,
are signiﬁcantly decreased by treatment with S-44029 or AG1478 (Fig.
4c, p b 0.05 or p b 0.01). These inhibitors also signiﬁcantly reduced the
mRNA expression level of the goblet cell marker MUC2 in LS174T cells
(Fig. 4d, p b 0.05 or p b 0.01). These data suggest that the ADAM17–
EGFR signaling is involved in maintaining or promoting the goblet cell
differentiation in addition to cell proliferation.
We then examined the impact of the EGFR downstream pathways
on colonic epithelial cell proliferation and goblet cell differentiation by
treating LS174T cells with inhibitors for the mitogen activated protein. Effect of ADAM17-selective (20 μM, S-44029) or EGFR-speciﬁc (20 μM, AG1478) inhibitor
rol. b. Time-lapse cell growth assay showing the effect of S-44029 or AG1478 inhibitor on
r AG1478 inhibitor onmucus production in LS174T cells. Representative Alcian-Blue (AB)-
el. Scale bars, 20 μm. The ratio of AB-positive area in the total cell areawas also determined
478 inhibitor onMUC2 expression in LS174T cells. Relative gene expression of MUC2was
ll growth assay showing the effect of MEK-speciﬁc (10 μM, U0126), PI3K-speciﬁc (20 μM,
ean ± s.d.; n = 3 wells; *, p b 0.05; **, p b 0.01. U0124 (10 μM) was used as a control for
(S3I) on MUC2 expression in LS174T cells. The expression of MUC2 was evaluated by dot
0.01. U0124 was used as a control for U0126. GAPDHwas used as a loading control for dot
ent's t-test, and comparisons among three or more groups were determined by one-way
espective plots.
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transducer and activator of transcription 3 (STAT3) signaling, all
of which are pathways downstream of EGFR. As shown in Fig. 4e,
time-lapse cell growth analysis indicated that cell growth of Caco-2
and LS174T cells is signiﬁcantly reduced by treatment with MEK
inhibitor (U0126), PI3K inhibitor (LY294002) or STAT3 inhibitor
(S3I) compared to controls or those treated with a negative control
agent (U0124). In addition, U0126 or S3I also signiﬁcantly down-
regulated the expression of MUC2 in LS174T cells, while LY294002
showed no effects on MUC2 expression (Fig. 4f, p b 0.01).
3.6. ADAM17 Knockdown Reduces EGFR Signaling in Colonic Epithelial Cells
We asked whether speciﬁc knockdown of ADAM17 expression by
siRNAs affects the cell growth and goblet cell phenotype in colonic
epithelial cell lines. When Caco-2 and LS174T cells were transfected
with siRNAs for ADAM17 (siADAM17#1 and siADAM17#2) or control
non-silencing siRNA, ADAM17-targeting siRNAs effectively reduced
the level of ADAM17 and pEGFR when compared to non-silencing
control (Fig. 5a). Importantly, ADAM17-knockdown cells demonstrated
signiﬁcantly reduced cell growth (Fig. 5b, p b 0.01), decreased Alcian-
Blue-positive mucin production, and MUC2 expression in LS174T cells
(Fig. 5c and d, p b 0.01).
3.7. Ectopic EGFR Stimulation Partially Rescues Severe Colitis in
Adam17ﬂox/ﬂoxMx1-Cre+ Mice
We further asked whether injection of recombinant TGF-αwould
rescue the severity of intestinal inﬂammation in DSS-treated
Adam17ﬂox/ﬂoxMx1-Cre+ mice. As shown in Fig. 6a, Adam17ﬂox/ﬂoxMx1-
Cre+ mice treated with recombinant TGF-α showed less weight loss
than those treated with PBS (p b 0.01). Histological analysis demon-
strated that mean areas of Grade III lesion are signiﬁcantly decreasedFig. 5. ADAM17 knockdown inactivates EGFR signaling and reduces cell proliferation and goble
transfected with ADAM17-speciﬁc siRNAs #1 and #2 or non-silencing siRNA. β-Actin was u
knockdown by siRNAs on Caco-2 and LS174T cell growth. Bars, mean ± s.d.; n = 3 wells; **, p
Mucus production was evaluated by Alcian-Blue (AB) staining (left panel). Scale bars, 20 μ
mean ± s.d.; n = 4 dishes; **, p b 0.01. d. Effect of ADAM17 knockdown by siRNAs on MUC2
Bars, mean ± s.d.; n = 3 dishes; **, p b 0.01. Results between the two independent groups w
determined by one-way ANOVA followed by Bonferroni's post-hoc testing. P values smaller thain Adam17ﬂox/ﬂoxMx1-Cre+ mice upon injection of recombinant TGF-α
compared to PBS-injected mice (Fig. 6b, p b 0.01). Concomitantly,
TGF-α injection restored Alcian-Blue-positive mucus production by ep-
ithelial cells to a degree, which was markedly decreased in PBS-treated
Adam17ﬂox/ﬂoxMx1-Cre+mice after DSS administration (Fig. 6c,p b 0.05),
suggesting that adequate EGFR stimulation could be a potential avenue
of therapeutic intervention.
3.8. ADAM17 is Upregulated in Colonic Epithelia of UC Patients
Finally, to address the relevance of our ﬁndings to human UC, we
investigated by immunohistochemistrywhether ADAM17 is upregulated
by colonic epithelia in UC as compared to normal epithelia of colonmuco-
sae, which were obtained from the colon remote from colon cancer.
ADAM17 was strongly immunostained in cytokeratin AE1/AE3 positive-
epithelial cells of the colon in UC patients, while only negligible staining
was seen in the colonic mucosa from control subjects (Fig. 7a and
data not shown for AE1/AE3 staining). Similar expression pattern
was observed for pEGFR, while expression of total EGFRwas comparable
in both UC and normal colonic mucosae. When the immunohistochem-
ical staining for ADAM17was evaluated by the scoring system described
in the Methods, the mean score of epithelial ADAM17 expression was
signiﬁcantly higher in the UC patients than in the control (Fig. 7b,
p b 0.01) and this score trended lower in UC patients under remission,
although not signiﬁcantly different. We also analyzed correlations
of Ki-67-positive cell index and number of goblet cells between
ADAM17-low and ADAM17-high groups of active UC patients. As
shown in Fig. 7c, ADAM17-high expression group showed higher
Ki-67-positive cell index (p b 0.01) and an increased number of goblet
cells (p b 0.05) compared to the ADAM17-low expression group.
All these immunohistochemical data are in accord with the ﬁndings
obtained in ourmousemodel, and support our hypothesis on the protec-
tive actions of ADAM17 in colitis.t cell phenotype. a. Immunoblot of ADAM17, pEGFR and EGFR in Caco-2 and LS174T cells
sed as a loading control. b. Time-lapse cell growth assay showing the effect of ADAM17
b 0.01. c. Effect of ADAM17 knockdown by siRNAs on mucus production in LS174T cells.
m. The ratio of AB-positive area in the total cell area is determined (right panel). Bars,
expression in LS174T cells. Relative gene expression of MUC2 was examined by RT-qPCR.
ere determined by Student's t-test, and comparisons among three or more groups were
n 0.05 are indicated on respective plots.
Fig. 6. Ectopic EGFR stimulation reduces severe colitis in Adam17ﬂox/ﬂoxMx1-Cre+mice. a. Percentweight change of PBS-treatedAdam17ﬂox/ﬂoxMx1-Cre+ (ΔAdam17_Mx1) (n=6mice) and
TGF-α-treatedΔAdam17_Mx1mice (n=6mice) afterDSS administration.ΔAdam17_Mx1micewere intraperitoneally injectedwith recombinant TGF-α (8 μg per injection) orwith PBS at
days 0, 2, 4 and 6 after DSS administration. Bars, mean ± s.d.; **, p b 0.01. b. Grade III lesions in PBS-treated ΔAdam17_Mx1 (n= 3 colon tissues) and TGF-α-treated ΔAdam17_Mx1mice
(n = 3 colon tissues) at day 8 after DSS administration. Bars, mean ± s.d.; **, p b 0.01. c. Images and quantiﬁcation of colonic goblet cells in PBS-treated control and TGF-α-treated
ΔAdam17_Mx1mice at day 8 after DSS administration. Representative HE- and Alcian-Blue (AB)-stained colon sections from control and TGF-α-treated ΔAdam17_Mx1mice at day 8
after DSS challenge are indicated in the left panel. Note that AB-positive mucus production is restored in ΔAdam17_Mx1 mice by TGF-α administration. Scale bars, 50 μm.
Quantiﬁcation of number of AB-positive goblet cells per 100 epithelial cells is shown in the right panel. Bars, mean ± s.d.; n = 3 colon tissues; *, p b 0.05. Results between the two
independent groups were determined by Student's t-test. P values smaller than 0.05 are indicated on respective plots.
121M. Shimoda et al. / EBioMedicine 5 (2016) 114–1244. Discussion
In the present study, we have developed DSS-induced colitis in two
different conditional Adam17-deﬁcient mice, and demonstrated that
ADAM17 derived from epithelial cells, but not myeloid cells, confers
resistance to colitis by driving repair processes through epithelial cell
proliferation and goblet cell differentiation. We propose that EGFR
activation and its signaling pathways initiated by ADAM17 contribute
to the repair of damaged epithelial cells andmaintenance of the epithe-
lial barrier in human UC (Supplementary Fig. 6).
Chalaris et al. developed hypomorphic ADAM17 mice (Adam17ex/ex
mice) that resulted in aggravation of DSS-induced colitis. This study
suggested that the impaired phosphorylation of STAT3 via EGFR activa-
tion in epithelial cells is implicated for the increased sensitivity to DSS-
induced colitis (Chalaris et al., 2010). However, themice had abnormal-
ities in the eyes, heart and hair follicles during their development, and
more importantly, they developed spontaneous inﬂammation of the
skin. Since DSS-induced colitis is known to generate systemic responses
in mice (Dong et al., 2013), unexpected responses to DSS due to the
innate inﬂammatory features are likely to be superimposed on top of
the colitis induced by this model. Adam17wavedX/wavedX mice generated
by Brandl et al. also showed severe weight loss during DSS administra-
tion (Brandl et al., 2010), and the authors demonstrated that ADAM17-
mediated EGFR signaling in non-hematopoietic cells plays a protective
role against DSS-induced colitis. Although the study provided noinformation about which cell types in the non-hematopoietic compart-
ment are responsible for the accelerated colitis, we have disclosed
that ADAM17 derived from colonic epithelial cells is essential for
these processes, and further demonstrated the relevance of the experi-
mental ﬁndings to human UC tissues.
Epithelial regeneration is a key process for the recovery from IBDs,
and is one of the most signiﬁcant prognostic factors for long-term
remission (Lichtenstein and Rutgeerts, 2010). Epithelial cell prolifera-
tion during regeneration is stimulated by several growth factors
produced by local epithelial and mesenchymal cells in crypts near the
damaged mucosal area. EGFR ligands are one major group of growth
factors involved in rapid expansion of crypt epithelial cells, and they
are secreted mainly from epithelial cells surrounding the damaged
epithelial region (Okamoto and Watanabe, 2005). Previous studies
showing that defective EGFR signaling in mice deﬁcient for TGF-α
leads to severe inﬂammation upon DSS challenge (Egger et al., 1997)
and overexpression of TGF-α reduces susceptibility of DSS-induced
colitis (Egger et al., 1998) have suggested that TGF-α acts as a principal
growth factor for protection from colitis. In the present study, TGF-α
was overexpressed by the colonic epithelial cells in both DSS-
administered control and Adam17ﬂox/ﬂoxMx1-Cre+ mice, but aggravation
of the colitis was observed only in the latter mouse group. The severity
of colitis in DSS-treated Adam17ﬂox/ﬂoxMx1-Cre+ mice was partially
rescued by treatment with recombinant TGF-α. Since ADAM17 is the
major sheddase formembrane-type TGF-α and its shedding is suppressed
Fig. 7.ADAM17 is upregulated in colonic epithelia of UC patients. a. Representative colon sections fromcontrol normal subjects orUCpatientswhich are stainedwithHEor immunostained
for ADAM17, pEGFR and EGFR. NI, non-immune IgG. The highlighted areas are magniﬁed to the lower. Scale bars, 100 μm. b. ADAM17 expression score in colonic epithelia from control
subjects (n = 30 patients), the patients with active UC (n= 25 patients) or under remission (n = 4 patients). Bars, mean ± s.d.; **, p b 0.01. c. Correlations between epithelial ADAM17
expression levels (ADAM17-low (n= 11 patients) and -high groups (n= 14 patients) of active UC patients) and Ki-67-positive cell index (left panel) or number of goblet cells per 100
epithelial cells (right panel). Bars, mean± s.d.; *, p b 0.05; **, p b 0.01. Results between the two independent groups were determined by Student's t-test, and comparisons among three or
more groups were determined by one-way ANOVA followed by Bonferroni's post-hoc testing. P values smaller than 0.05 are indicated on respective plots.
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of the colitis in Adam17ﬂox/ﬂoxMx1-Cre+ mice could be explained by the
inability of the colonic epithelia to activate TGF-α.
One of our most intriguing ﬁndings in the present study is that
decreased goblet cell differentiation andmucus productionwere associ-
atedwith severe inﬂammation in response to DSS in Adam17ﬂox/ﬂoxMx1-
Cre+ mice. Complete knockout of the Adam17 gene displays multiple
pathological changes in several organs, resulting in disturbed develop-
ment of the eyes, lung, heart, immune system, hair and skin (Peschon
et al., 1998). The phenotype is ascribed to result from disturbance of
cell differentiation and tissue development, which may be caused by
failure of ADAM17 to activate EGFR. This ADAM17-EGFR axis has been
reported to regulate terminal differentiation of keratinocytes (Franzke
et al., 2012) and chondrocytes (Hall et al., 2013) and oligodendrogenesis
during postnatal myelination (Palazuelos et al., 2014). Our data indicate
that this axis also enhances goblet cell differentiation of colon epithelial
cells during inﬂammation.
Repair of the damaged intestinal epithelium is carried out by two
continuous steps, i.e. restitution by proliferated epithelial cells and
subsequent maturation into functionally differentiated epithelial cells
(Okamoto and Watanabe, 2005). We have shown that the ADAM17-
EGFR axis commands both the processes through different EGFR-
downstream signaling pathways. All the MAPK, STAT3 and PI3K
pathways were required for epithelial cell proliferation, but the PI3K
pathway was dispensable for goblet cell differentiation. ADAM17 is
implicated in the shedding of ﬁve of the seven EGFR ligands (TGF-α,
epiregulin, epigen, amphiregulin and HB-EGF) (Sahin and Blobel, 2007,Sahin et al., 2004). Therefore, it might be possible that the shedding of
diverse EGFR ligands by ADAM17 may sequentially control epithelial
cell proliferation and differentiation. Further in vivowork is needed to
gain deeper mechanistic insight.
The integrity of the epithelial barrier is maintained mainly by tight
junctions (Laukoetter et al., 2008). However, the barrier is reinforced
by several factors, which are dependent on multiple types of epithelia.
In colon mucosa, mucin plays a key barrier function by coating the
epithelium and preventing entry of microbes (Laukoetter et al., 2008).
Genome-wide association studies showed that genetic mutations of
MUC2, the most abundant protective mucin, are associated with UC
(Abraham and Cho, 2009). Our data on the goblet cell differentiation
and MUC2 expression have indicated that ADAM17 supports mucosal
epithelial barrier functions mostly by promoting mucus production. In
the skin, keratin layer formed by keratinocytes is known to have a
supportive role in the epidermal barrier. Recent experimental studies
provided mechanistic evidence that keratinocyte-derived ADAM17
strengthens the epidermal barrier function by increasing keratin
cross-linking through the activation of transglutaminase 1 (TGM1)
(Franzke et al., 2012), and promotes resistance to bacterial infection
(Brooke et al., 2014). Although no direct evidence is available for the
relationship between TGM1 expression and intestinal barrier function,
TGM1 is known to be downregulated in the colon of UC patients
(D'argenio et al., 2005). Interestingly, patients with ulcerative colitis
are reported to have a higher risk for skin disorders (Huang et al.,
2012). Altogether, these data suggest the possibility that ADAM17
plays an important role in maintaining the barrier function of both
123M. Shimoda et al. / EBioMedicine 5 (2016) 114–124colon and skin. In this context, the recently reported autosomal recessive
disease linked to ADAM17 deletion (Blaydon et al., 2011), in which
patients exhibit severe inﬂammatory skin lesions and symptoms of
bowel disease such as diarrhea, seems to support this hypothesis, since
these symptoms may be triggered by challenges to defective epithelial
barriers of the skin and intestine.
A potential limitation of this study was the use of the DSS-induced
colitis model as a clinically relevant model. Although DSS-induced
colitis is a disease model resembling human UC, T and B cells are not
involved in development of the colitis, indicating that adaptive immuni-
ty is not required for this model (Chassaing et al., 2014). Nevertheless,
DSS-induced colitis model may be useful for studying the contribution
of the epithelial barrier function and innate immune system to the initi-
ation of colitis, and our results suggest that epithelial cell-derived
ADAM17 is essential for repair processes through epithelial cell prolifer-
ation and goblet cell differentiation. Regulation mechanisms for the
ADAM17 expression by colonic epithelial cells during colitis also remain
unclear in this study. Previous studies suggested that TNF-α and
wild-type p53 up-regulate ADAM17 expression (Guinea-Viniegra
et al., 2012, Charbonneau et al., 2007), but further studies are needed
to determine regulators of ADAM17 in intestinal inﬂammation.
Treatments against TNF-α exhibit a remarkable clinical response
in some UC patients (Danese et al., 2013), but the majority of emerging
selective ADAM17 inhibitors which target TNF-α shedding in human
inﬂammatorydiseases arenot successful (Duffy et al., 2011). The informa-
tion in the present study that epithelial cell-derived ADAM17 is required
for colonic epithelial regeneration and barrier function indicates that
remedies targeting speciﬁcally stromal cells, but not epithelial cells,
would be necessary to avoid negative consequences during clinical trials
of ADAM17 inhibitors in UC patients. In addition, this work provides
important mechanistic insight for goblet cell- and mucin-based therapy
to protect the epithelial barrier and compensate for impaired epithelial
regenerative activity when ADAM17 inhibitors are introduced.Funding Sources
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